ArticleLeukemia research reports2022

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study.

Jing Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.